Iwata, H, Baselga, J, Campone, M, Arteaga, CL, Cortes, J, Jonat, W, De Laurentiis, M, Ciruelos, E, Janni, W, Bachelot, T, Lonning, PE, Ma, C, O'Regan, R, Di Tomaso, E, Bharani-Dharan, B, Duval, V, Lau, H, Germa, C, Urban, P and Di Leo, A (2013) Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. Journal of Clinical Oncology.

Item Type:	Article
Additional Information:	NIBR author: institute: NIBR contributor address: Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Inst Cancerol Ouest Rene Gauducheau, St Herblain, France. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Vall dHebron Inst Oncol, Barcelona, Spain. Univ Kiel, Kiel, Germany. Natl Canc Inst Fdn Pascale, Naples, Italy. Univ Hosp 12 Octubre, Madrid, Spain. Univ Ulm Klinikum, Ulm, Germany. Ctr Leon Berard, F-69373 Lyon, France. Haukeland Hosp, N-5021 Bergen, Norway. Washington Univ, Sch Med, St Louis, MO USA. Emory Univ, Sch Med, Atlanta, GA USA. Novartis Inst Biomed Res Inc, Cambridge, MA USA. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. Novartis Oncol, Paris, France. Sandra Pitigliani Hosp Prato, Prato, Italy.
Date Deposited:	13 Oct 2015 13:12
Last Modified:	13 Oct 2015 13:12
URI:	https://oak.novartis.com/id/eprint/23432